F. Huber 1 * , H. P. Lang 1 , N. Backmann 1 , D. Rimoldi 2 † and Ch. Gerber 1 † Malignant melanoma, the deadliest form of skin cancer, is characterized by a predominant mutation in the BRAF gene [1] [2] [3] . Drugs that target tumours carrying this mutation have recently entered the clinic [4] [5] [6] [7] . Accordingly, patients are routinely screened for mutations in this gene to determine whether they can benefit from this type of treatment. The current gold standard for mutation screening uses real-time polymerase chain reaction and sequencing methods 8 . Here we show that an assay based on microcantilever arrays can detect the mutation nanomechanically without amplification in total RNA samples isolated from melanoma cells. The assay is based on a BRAF-specific oligonucleotide probe. We detected mutant BRAF at a concentration of 500 pM in a 50-fold excess of the wild-type sequence. The method was able to distinguish melanoma cells carrying the mutation from wild-type cells using as little as 20 ng ml -1 of RNA material, without prior PCR amplification and use of labels.
In the past decade, the identification of alterations in specific signalling pathways and recurrent oncogenic mutations in particular types of cancers has led to the explosion of targeted therapy approaches. In cutaneous melanoma, a significant improvement in overall survival has been achieved by the use of vemurafenib and similar drugs that selectively inhibit tumours carrying a mutated BRAF gene 4, 5 . Further drugs for combination therapies with higher efficacies and fewer side effects are in clinical trials 6 . BRAF is one of three RAF genes (rapidly accelerated fibrosarcoma A, B and C) encoding cytoplasmic protein serine/threonine kinases belonging to the mitogen-activated protein kinase (MAPK) signal transduction cascade, a pathway controlling various cellular processes such as proliferation, migration and survival 1, 7 . BRAF somatic mutations are present in half of cutaneous melanomas. Over 90% of the mutations are a single T to A transversion at position 1799 in the BRAF coding sequence (cT1799A), which converts a valine amino-acid residue at position 600 in the protein to a glutamic acid (V600E). This mutation renders the protein constitutively active, resulting in a deregulated MAPK pathway 2 and thus uncontrolled cell growth and cancer. BRAF mutations are also present in other neoplasms, including hairy cell leukaemias, and thyroid and colon carcinomas 3, 9, 10 . As the presence of the cT1799A/V600E BRAF (hereafter BRAF V600E ) mutation determines eligibility for BRAF inhibitor treatment, molecular screening of tumour biopsies is now carried out routinely. Various methods have been developed for the detection of the BRAF V600E mutation at the DNA level. Among them is the longestablished procedure of polymerase chain reaction (PCR) amplification coupled with Sanger sequencing of the product. The standard test currently used to analyse patients' biopsies before initiation of vemurafenib treatment relies on real-time PCR (the COBAS Test 8 ), whereby 5-10% of BRAF-mutated melanoma cells can be detected in a background of normal cells. Alternative technologies to classic methods are under development, such as cycling temperature capillary electrophoresis 11 (with sensitivity comparable to COBAS), silicon nanowire field-effect transistors 12 and a threedimensional gold nanowire platform 13 . The latter technologies have only been shown to work using synthetic oligonucleotide targets or larger gene fragments, or indeed still rely on an initial PCR amplification. In particular, they have not been applied to the direct identification of a mutated messenger RNA (mRNA) sequence in total RNA (constituted primarily by ribosomal RNA and containing all mRNAs transcribed from genes) or DNA samples.
In recent years, a versatile platform for biodetection has been developed based on microfabricated arrays of silicon cantilevers [14] [15] [16] [17] [18] [19] [20] [21] , each coated with a sensitive layer for molecular recognition, for example, a gene-specific oligonucleotide. The binding of the target sequence is mechanically transduced to the cantilever surface, resulting in bending of the cantilever. Such devices comprise ultrasensitive sensors for the detection of biochemical interactions in liquid environments 22 . Here we have explored the feasibility of applying this technology to discriminate between BRAF V600E and wild-type BRAF sequences in melanoma samples.
In a first set of experiments aimed at assessing the specificity of detection of the BRAF V600E mutation with cantilever arrays, we chose as a probe a surface-immobilized thiolated 13-mer oligonucleotide (V600E_short; Table 1 ) carrying at its centre the mutated nucleotide (adenine instead of thymidine, labelled in red). The short length is sufficient to provide a unique sequence that is not present anywhere else in the BRAF PCR product, and a central position of the mismatch was selected as it allows the highest discrimination between the wild-type and the mutant sequence. To ensure a high surface density of the BRAF-specific probe layer, preliminary tests were performed to optimize the adsorption of V600E_short thiol oligonucleotide probes onto a gold-coated cantilever surface (Supplementary Figs S1 and S2). Based on the results obtained, we decided to use the highest concentration (40 mM), corresponding to over 90% occupancy 23 , thus ensuring a large cantilever bending signal in all subsequent hybridization experiments. We also confirmed the reusability of the sensor by repeated injections of a 13-mer complementary oligonucleotide preceded by urea washing steps ( Supplementary Fig. S3 ).
We applied the array functionalized as shown in Fig. 1 to distinguish between wild-type and mutated BRAF sequences. For these experiments, we used PCR-amplified cDNA (complementary DNA derived from mRNA by reverse transcription) samples (BRAF V600E PCR, 621 base pairs (bp) long) derived from melanoma cells expressing either wild-type BRAF or mutant BRAF V600E . Figure 2a shows the differential signals obtained after injection of pure wild-type or mutated BRAF sequences, as well as after injection of increasing dilutions (wild type-to-mutant ratios from 1:1 to 50:1) of the mutated into the wild-type sequence. The cantilevers selectively responded to the mutated BRAF sequence, and the amplitude of deflection scaled with the concentration of target DNA or RNA. Furthermore, the mutant gene sequence could still be detected in the presence of a 50-fold excess of wild-type DNA sample (that is, when present at the 2% level). In each experiment the total DNA concentration was kept constant at 10 ng ml 21 . As the size of the fragments used was 621 bp, corresponding to a molecular weight of 4 × 10 5 Da, the results indicate a detection limit of 500 pM BRAF V600E DNA in the presence of excess wild-type sequence. Figure 2b shows the Langmuir isotherm fitted to the equilibrium values of responses extracted from Fig. 2a , plotted against the concentration of BRAF V600E PCR product. The dG value of 249.8 kJ mol 21 calculated from the Langmuir plot is in good agreement with results previously reported for hybridization experiments with oligonucleotides of similar length using microcantilevers (dG ¼ 241.4 kJ mol 21 ) 15 and surface plasmon resonance (SPR) data (dG ¼ 243.4 kJ mol 21 ) 24 , as well as theoretical calculations in solution (dG ¼ 250.5 kJ mol 21 ) 25 . The minor deviation of our measurement from these values can be explained by the double-stranded nature and length of the fragments analysed.
Messenger RNAs are present in cells at a higher copy number than the corresponding genes. In addition, RNA/DNA interactions are stronger than DNA/DNA interactions 26 . We thus directly detected the BRAF mutation at the RNA level without prior amplification steps (for example, PCR). For this purpose we designed an oligonucleotide probe to unambiguously identify the mutated BRAF (1) the silicon array is coated with PEG-silane (brown ovals) to prevent non-specific adsorption to the lower cantilever side;
(2) the array is coated with titanium as an adhesion layer and gold (in yellow) for thiol binding; (3) the cantilevers are either functionalized with a probe oligonucleotide (in red) or a non-specific reference oligonucleotide (in light blue); (4) injection of the target DNA (a) or RNA (b) containing the complementary (matching) sequence (depicted in green) to the probe oligonucleotide (red). Non-related sequences are shown in black.
On hybridization, only the probe cantilever bends, giving rise to a differential deflection Dx. No binding occurs on the reference cantilever. mRNA sequence. Based on the expressed sequence tags database of the human genome we determined a minimum required length of 18 bases to specifically detect BRAF mRNA. As total RNA is a more complex sample than uniform PCR products, longer oligonucleotide probes were chosen to avoid cross-reactivities and thus assure specificity. The cantilevers were therefore functionalized with the corresponding 18-mer thiol oligonucleotide probe (Table 1) and an 18-mer reference oligonucleotide (polyAC_long). The use of reference cantilevers is mandatory to eliminate temperature drift, unspecific binding and refractive index changes. Total RNA samples extracted from melanoma cell lines carrying wild-type (T618A) or mutated (SK-Mel-37) BRAF sequences were injected at different concentrations, ranging from 5 to 300 ng ml 21 . The results of these experiments are shown in Fig. 3a-d . Four concentrations in the range 5-300 ng ml 21 were measured, suggesting a lower limit of detection between 5 and 20 ng ml 21 total RNA. Best specificities were achieved at 100 and 20 ng ml 21 total RNA (Fig. 3b,c) . As BRAF-mutated cancer cells still retain a normal copy of the wild-type BRAF gene that can still be expressed, at variable levels, alongside the mutated form, using a wild-type BRAF oligonucleotide as a reference instead of polyAC_long provides an important control. Using the corresponding 18-mer wild-type oligonucleotide as reference, we observed a reduced response in the SK-Mel-37 signal (purple curve) compared to the poly-AC differential signal (blue curve, Fig. 3e ), consistent with a certain level of wild-type BRAF expression in these cells (estimated at 20% from Sanger sequencing plots, as shown in Supplementary  Fig. S4 ). A positive signal (green curve) was observed using T618A RNA (BRAF wild-type), as expected, due to binding to the wild-type oligonucleotide (Fig. 3f ) . The increased noise observed during sample injection is probably due to the complexity of the total RNA samples. We further extended the RNA experiments to additional cell lines carrying either BRAF V600E or wild-type BRAF sequences. Figure 4a ,b shows the results of experiments performed by injecting total RNA (at a concentration of 100 ng ml 21 ) extracted from three different mutant cell lines (SK-Mel-37, Me246.M1 and Me275) and two different wild-type cell lines (T618A and T1405B), respectively. The signals from the mutant cell lines differ substantially from those of the wild-type ones. The stronger deflection observed for SK-Mel-37 compared to the other two mutant cell lines correlates with the higher BRAF levels expressed by these cells (see Methods). The results demonstrate the robustness of the assay to readily distinguish BRAF-mutated from BRAF wild-type cell lines.
In summary, the experiments with melanoma samples demonstrate that mutant BRAF V600E can be identified in PCR products , mutant and wild-type sequences cannot be clearly distinguished, indicating increased cross-hybridization by the wild-type sequence. We are able to reliably distinguish mutant BRAF from wild-type BRAF at concentrations of 100 and 20 ng ml 21 (b,c). A signal of 4 nm at a total RNA concentration as low as 5 ng ml 21 was observed (d), indicating a limit of detection between 5 and 20 ng ml 21 . e, Experiments using total RNA from SK-Mel-37 cells and poly-AC (blue dots) or wild-type (purple dots) oligonucleotides as references, respectively (light grey bars indicate buffer and the orange bar indicates SK-Mel-37 sample injection). f, Response of total RNA to wild-type T618A (injection of sample indicated by light green bar at the bottom) is shown using a wild-type oligonucleotide reference (green dots). Here we show that the assay can distinguish between wild-type and mutant BRAF mRNA in a complex background of non-related sequences.
as well as in total RNA extracted from mutant cancer cell lines. The low concentration of total RNA required for the assay described here (20 ng ml 21 ) indicates that this approach is applicable to clinical material. Accordingly, this methodology could simplify and speed up the identification of tumours, reducing time to treatment. Although we have focused here on the detection of BRAF V600E mutations in melanoma, the microcantilever approach can be extended to other relevant mutations recurring in other types of cancer (for example, mutations in KIT, a receptor tyrosine kinase gene, in gastrointestinal stromal tumours and in epidermal growth factor receptor mutations in lung cancer 27 ). The proposed method has the following advantages: (i) samples do not have to be labelled or pre-amplified by PCR, as total RNA samples can be utilized;
(ii) the technique is cost-efficient; (iii) because of the array format the analysis can be paralleled, so the presence of multiple mutations may be interrogated simultaneously, allowing a more detailed clinical prognosis, facilitating fast and personalized medical diagnostics.
Methods
Sensor preparation. Microcantilever arrays of eight silicon cantilevers (500 mm long, 100 mm wide and 1 mm thick), fabricated at IBM Research, were used in the experiments. To coat the microcantilever arrays with a receptor layer, we used a previously described procedure 28 . Briefly, the arrays were cleaned in Piranha solution (30% H 2 O 2 :96% H 2 SO 4 ¼ 1:1, vol/vol) for 15 min, rinsed three times with water followed by isopropanol, then dried in air. The arrays were then incubated for 30 min in 10 mM 2-[methoxypoly (ethyleneoxy)propyl] trimethoxysilane (7 ethylene glycol units, ABCR) solution in dry ethanol to reduce non-specific binding to the lower silicon side. The array was then rinsed with isopropanol and dried in air. The upper sides of the cantilevers were subsequently coated with a 2 nm layer of titanium followed by a 25 nm gold layer, without breaking the vacuum. Deposition of metal layers was performed in an EVA 300 electron beam evaporator (Alliance Concept) at an evaporation rate of 0.1 nm s 21 .
Gold-coated arrays were used immediately.
Probes. Oligonucleotides functionalized at the 5 ′ end with a thiol group via a hexyl spacer were obtained from Microsynth. The synthetic oligonucleotides used in this work are described in Table 1 . Oligonucleotides were dissolved in 50 mM triethyl ammonium acetate buffer (TEAA, Fluka), pH 7, at a concentration of 40 mM. It is of paramount importance that measurements are performed in a differential fashion. External factors such as non-specific interactions and thermal drift are cancelled out by calculating the differential response of a probe and a reference cantilever (in this study derivatized with a non-specific oligonucleotide of the same length as the probe sequence or, in some experiments, with a wild-type sequence). Eight microcapillaries (outer diameter, 250 mm; inner diameter, 150 mm; King Precision Glass ) were filled with the appropriate oligonucleotide solution (probe or reference) to functionalize the cantilevers either with a probe layer or a reference layer. The cantilever array was then washed in 0.01× sodium-buffered saline citrate (SSC, Fluka), 1.5 mM NaCl, and used directly for the analysis.
DNA and RNA sample preparation. Cell lines from melanoma metastases were established at LICR, except for SK-Mel-37 (a gift from Y.T. Chen, New York). SK-Mel-37, Me275 and Me246.M1 harbour mutated BRAF (cT1799A/V600E), while T618A and T1405B carry wild-type BRAF, as assessed by Sanger sequencing. Total BRAF mRNA expression relative to T618A (set at 1) was 1.2, 0.9, 2.5 and 0.7 for Me275, Me246.M1, SK-Mel-37 and T1405B, respectively, as estimated by RNAseq 29 and/or PCR. Wild-type or mutated BRAF DNA sequences (621 bp, spanning exon 13-18) were generated by PCR amplification of cDNA prepared from melanoma cell lines (T618Aand SK-Mel-37) as previously described 30 . Amplified products were concentrated by two rounds of ammonium acetate/ethanol precipitation and dissolved in TE buffer. Total RNA was extracted using Trizol reagent (Invitrogen) following the manufacturer's instructions. RNA was further purified by ammonium acetate/ethanol precipitation and dissolved in DEPC-treated H 2 O.
Before the experiments, the PCR amplified fragments were denatured at 96 8C for 10 min and cooled in an ice bath, forming single-stranded segments along the DNA to enable hybridization. Similarly, total RNA was heated to 70 8C for 5 min and cooled, denaturing the three-dimensional structure of the RNA molecules to facilitate hybridization.
Sensor instrument. The functionalized array was inserted into a liquid chamber (volume, 15 ml), and cantilever bending was measured using time-multiplexed vertical-cavity surface-emitting lasers (VCSELs; wavelength 760 nm, Avalon Photonics). The laser beam was deflected to a position-sensitive detector (PSD, SiTek). Data were acquired using a multifunctional data-acquisition board (National Instruments) driven by LabView software. The software also controlled the liquid handling system of the setup, the syringe pump (GENIE, Kent Scientific) and a 10-position valve system (Rheodyne). The entire setup was placed inside a temperature-controlled box (Intertronic; Interdiscount), equilibrated through a fuzzy logic controller by the LabView software to keep the inside of the box at a temperature of 23 8C (accuracy of + 0.02 8C).
Measurement and data analysis. Hybridization experiments for the PCR DNA fragments were conducted in 5× SSC, and total RNA hybridization was carried out in 0.01× SSC. A volume of 450 ml was injected at a continuous flow (rate, 5-10 ml min 21 ). The bimetallic response and mechanical properties of the cantilevers were assessed by applying 0.3 V to a Peltier element situated directly below the chamber for 70 s (thermal cycle). This resulted in a 2 8C pulse for deflection calibration. The average of all cantilevers together with the largest T618A wild-type total RNA T1405B wild-type total RNA Bu er 100 ng μl −1 total RNA SK-Mel37 V600E total RNA Me275 V600E total RNA Me246.M1 V600E total RNA Bu er 100 ng μl −1 total RNA Figure 4 | Analysis of RNA samples from different BRAF mutated and wild-type tumour cells. Differential signals between probe (V600E_long functionalized) and reference (polyAC_long functionalized) cantilevers are shown. a,b, Total RNA from mutant BRAF V600E cell lines (a) consistently shows a higher signal than RNA from wild-type samples (b). After equilibrating the microcantilever array with 0.01× SSC buffer (light grey bar), 450 ml of total RNA (100 ng ml 21 ) was injected (orange bar). Dashed vertical lines indicate different injection periods. This experiment shows that the assay does not depend on the cell lines used; different BRAF mutant cell lines can be distinguished from wild-type cell lines.
response was used to normalize the signal, provided that the deflections did not differ by more than 10% in magnitude (usually six or more cantilevers satisfy this criterion). The normalized data from the reference cantilevers were subtracted from the data for the probe cantilevers to obtain a differential signal. A baseline correction (required because the drift behaviour of the different cantilevers varies slightly) was applied, using a linear fit of the data in the time interval beginning with buffer injection followed by DNA or RNA samples, respectively. The slope of the linear fit was subtracted from all differential signals.
